Cytokinetics, Incorporated
NASDAQ:CYTKBiotechnology
+$2.90 today
- Market cap
- $7.15B
- Beta
- 0.43
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$6.73
Volume 1.59M
Average 2.37M
CYTK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cytokinetics, IncorporatedNASDAQ: CYTK
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of $97.81M fell 13.1% year over year, behind the +0.9% change in trailing-twelve-month research & development. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.
Context
- Research & development amounted to 461.0% of revenue in FY2025, down 1376.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.1% toward the trailing-twelve-month pace of +0.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 405.9M USD
- Year-over-year change
- +19.6%
- 4-year CAGR
- +26.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 405.9M | +19.6% |
| FY2024 | 2024-12-31 | 339.41M | +2.8% |
| FY2023 | 2023-12-31 | 330.12M | +37.1% |
| FY2022 | 2022-12-31 | 240.81M | +50.6% |
| FY2021 | 2021-12-31 | 159.94M | — |
Research & Development vs competitors
How CYTK compares with its peers on the latest reported figures
- CYTK's LTM Jun 2026 research & development of $394.1M is the highest of the 3 companies compared; the peer median is $58.07M.
- Its year-over-year change of +0.9% is the highest of 2, against a peer median of -24.6%.
- Research & development amounts to 555.4% of revenue for CYTK, versus a peer median of 14005.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $394.1M | +0.9% | +19.0% | 555.4% | |
| LTM Mar 2026 | $62.37M | -24.6% | -10.1% | 27721.8% | |
| FY2025 | $53.76M | — | — | 288.7% | |
| — | — | — | — | — | |
| Peer median (excluding CYTK) | $58.07M | -24.6% | -10.1% | 14005.3% | |
Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M |
| Cost of Revenue | 159.94M | 240.81M | 330.12M | 339.41M | 10.13M |
| Gross Profit | (89.51M) | (146.23M) | (322.59M) | (320.93M) | 77.91M |
| Gross Margin | -127.1% | -154.6% | -4284.1% | -1737.2% | 88.5% |
| Research & Development | 159.94M | 240.81M | 330.12M | 339.41M | 405.9M |
| Selling, General & Admin | 96.8M | 177.98M | 173.61M | 215.31M | 284.27M |
| Operating Expenses | 96.8M | 177.98M | 173.61M | 215.31M | 690.17M |
| Depreciation & Amortization | 2.28M | 5.81M | 11.89M | 9.53M | 10.13M |
| EBITDA | (183.71M) | (331.99M) | (456.68M) | (493.48M) | (774.83M) |
| EBITDA Margin | -260.8% | -351.0% | -6064.9% | -2671.2% | -880.1% |
| Operating Income | (186.31M) | (324.2M) | (496.21M) | (536.25M) | (612.26M) |
| Operating Margin | -264.5% | -342.8% | -6589.7% | -2902.7% | -695.4% |
| Interest Income | 331K | 11.34M | 27.63M | 51.53M | 48.42M |
| Interest Expense | 29.33M | 51.16M | 57.67M | 86.51M | 103.87M |
| Other Income / Expenses | (29M) | (64.75M) | (30.04M) | (53.28M) | (172.7M) |
| Income Before Tax | (215.31M) | (388.96M) | (526.24M) | (589.53M) | (784.96M) |
| Pre-Tax Margin | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (215.31M) | (388.96M) | (526.24M) | (589.53M) | (784.96M) |
| Net Margin | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
| EPS (Basic) | (2.80) | (4.33) | (5.45) | (5.26) | (6.54) |
| EPS (Diluted) | (2.80) | (4.33) | (5.45) | (5.26) | (6.54) |
| Weighted Avg Shares | 76.89M | 89.83M | 96.52M | 111.98M | 120.02M |
| Weighted Avg Shares (Diluted) | 76.89M | 89.83M | 96.52M | 111.98M | 120.1M |
Cytokinetics, Incorporated
NASDAQ:CYTK
Intrinsic Alpha fair value
Locked
Current Price
$51.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.